Amphastar pharmaceuticals receives fda approval for naloxone hydrochloride nasal spray 4mg

Rancho cucamonga, ca / accesswire / march 8, 2023 / amphastar pharmaceuticals, inc. (nasdaq:amph) ("amphastar" or the "company") announced that the u.s. food and drug administration ("fda") has granted approval of its new drug application ("nda") for naloxone hydrochloride nasal spray 4mg, which is delivered utilizing the company's proprietary nasal delivery device. naloxone hydrochloride nasal spray 4mg is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression for adult and pediatric patients.
AMPH Ratings Summary
AMPH Quant Ranking